Lyra Therapeutics

Clinical trials sponsored by Lyra Therapeutics, explained in plain language.

Lyra Therapeutics LYRA NASDAQ

A clinical-stage biopharmaceutical company developing therapies for chronic ear, nose, and throat diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Completed 1

New sinus implant aims to unblock noses and ease facial pain

Symptom relief Completed

This study tested an experimental implant called LYR-210 in 182 adults with long-term sinus inflammation (chronic rhinosinusitis). The goal was to see if it could reduce key symptoms like nasal congestion, discharge, and facial pain better than a placebo. Participants received th…

Phase 3 • Sponsor: Lyra Therapeutics • Aim: Symptom relief

Last updated Jun 27, 2026 09:06 UTC

Lyra Therapeutics

New sinus implant aims to unblock noses and ease facial pain